Check out the companies making headlines before the bell. HealthEquity — Shares of the health-focused fintech company plunged 15% following weaker-than-expected fourth quarter earnings. HealthEquity, posted non-GAAP earnings per share of 69 cents on revenue of $311.8 million. Analysts polled by FactSet expected earnings of 72 cents per share on revenue of $305.8 million. General Mills — Shares lost more than 3% after General Mills lowered its full-year guidance and reported a top-line miss for the third quarter. The processed food company now sees organic net sales falling between 1.5% to 2% in the full-year, versus previous calls for flat sales to a 1% rise. General Mills cited inventory headwinds and softer demand as revenue of $4.84 billion in the third quarter missed a FactSet estimate of $4.96 billion. Goldman Sachs — The bank’s shares ticked nearly 1% lower on the heels of an Oppenheimer downgrade to perform from outperform. Oppenheimer cited the lack of a clear rebound in merger and acquisition activity as a key reason for the call. Gilead Sciences — The biopharmaceutical stock slipped 2.7% after the Wall Street Journal reported that the Health and Human Services Department is weighing plans to significantly slash the federal government’s funding for domestic HIV prevention. Gilead, which sells medicines for HIV and AIDS, sold off on the news. Tesla — The electric vehicle manufacturer advanced almost 3% after receiving approval from the California Public Utilities Commission for a passenger transportation permit. The company applied for the permit to offer ride hailing services, which could eventually lead to it providing robotaxi services, according to a report from Bloomberg. — CNBC’s Alex Harring and Jesse Pound contributed reporting
